OP0012 A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses

Abstract

BackgroundComparative effectiveness trials using suitable endpoints are necessary to demonstrate therapeutic equivalence of biosimilar molecules.ObjectivesThis phase 3 double-blind, active comparator, clinical trial compared the efficacy and safety of a biosimilar...